Factors associated with blindness three months following treatment for acute primary angle glaucoma

Br J Ophthalmol. 2021 Apr;105(4):502-506. doi: 10.1136/bjophthalmol-2020-316259. Epub 2020 Aug 7.

Abstract

Aims: To study the risk factors associated with blindness after treatment of acute primary angle closure (APAC), and to identify the critical time window to decrease rate of blindness.

Methods: In this multicentre retrospective case series, 1030 consecutive subjects (1164 eyes) with APAC in China were recruited. The rates of blindness were analysed up to 3 months after treatment of APAC. A logistic regression was used to identify the risk factors associated with blindness, including age, gender, distance to hospital, rural or urban settings, treatment method, education level, time from symptom to treatment (TST, hours) and presenting intraocular pressure (IOP). The critical time window associated with a blindness rate of ≤1% was calculated based on a cubic function by fitting TST to the rate of blindness at each time point.

Results: The rate of blindness after APAC was 12.54% after treatment. In multivariate regression, education level, TST and presenting IOP were risk factors for blindness (p=0.022, 0.004 and 0.001, respectively). The critical time window associated with a blindness rate of ≤1% was 4.6 hours.

Conclusions and relevance: Education level, TST and presenting IOP were risk factors for blindness after APAC. Timely medical treatment is key in reducing blindness after APAC.

Keywords: angle; glaucoma.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Aged
  • Blindness / epidemiology
  • Blindness / etiology*
  • China / epidemiology
  • Female
  • Follow-Up Studies
  • Glaucoma, Angle-Closure / diagnosis
  • Glaucoma, Angle-Closure / surgery*
  • Humans
  • Incidence
  • Intraocular Pressure / physiology*
  • Iridectomy / adverse effects*
  • Male
  • Postoperative Complications*
  • Retrospective Studies
  • Time Factors
  • Visual Acuity*